Interstitial lung disease (ILD) is a group of more than 200 ... Each of these conditions has unique symptoms and mechanisms, ...

Some of the more common types of interstitial lung disease include: Symptoms of interstitial lung diseases vary depending on the type of ILD and the severity of the disease. Once lung damage has ...

Baylor Medicine’s Interstitial Lung Disease (ILD) program offers specialized and multidisciplinary care. We bring together a unique team of physicians of multiple sub-specialties for patients with a ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...

Background: Data examining the role of pulmonary rehabilitation (PR) in interstitial lung disease (ILD) are limited. We tested the hypothesis that PR can improve functional status and dyspnea in a ...

Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

The following is a summary of “Diagnosis, screening, and follow-up of patients with familial interstitial lung disease: ...